Glenmark: Company Predicts Strong Increase In US Sales

 05 Aug 2026 09:45 AM

Glenmark: Company Predicts Strong Increase In US Sales

Glenmark: Company Estimates Quarterly US Sales Over $100 Million

 05 Aug 2026 09:47 AM

Glenmark: Company Estimates Quarterly US Sales Over $100 Million

Glenmark: Sets Margin Forecast For FY27 Between 21% And 22%

 05 Aug 2026 09:47 AM

Glenmark: Sets Margin Forecast For FY27 Between 21% And 22%

Glenmark: Company Reveals About 25% Of Its Sales Come From The US Market.

 05 Aug 2026 09:48 AM

Glenmark: Company Reveals About 25% Of Its Sales Come From The US Market.

Glenmark Pharma: Anticipates Over 18% Yearly Growth Excluding 2001 Deferred Income, North America Expected To Maintain Strong Recovery Boosted By Respiratory Products.

 04 Aug 2026 08:49 AM

Glenmark Pharma: Anticipates Over 18% Yearly Growth Excluding 2001 Deferred Income, North America Expected To Maintain Strong Recovery Boosted By Respiratory Products.

Glenmark Pharma: Expects High Single-Digit Growth In Europe This Year, Aiming For Double-Digit Growth Next Year With Increased Branded Launches. R&D Spending Will Stay Around 7%-8%, With IGI Investments Of About $70 Million Planned Over The Next Two To Three Years, Including Clinical Trials For 2301 Phase 1.

 04 Aug 2026 08:51 AM

Glenmark Pharma: Expects High Single-Digit Growth In Europe This Year, Aiming For Double-Digit Growth Next Year With Increased Branded Launches. R&D Spending Will Stay Around 7%-8%, With IGI Investments Of About $70 Million Planned Over The Next Two To Three Years, Including Clinical Trials For 2301 Phase 1.

Glenmark Pharma: Expects Operating Margins To Stay Between 21% And 22% For The Whole Year Despite Cost Pressures From Geopolitical Issues By Optimizing Product And Geographical Mix.

 04 Aug 2026 08:51 AM

Glenmark Pharma: Expects Operating Margins To Stay Between 21% And 22% For The Whole Year Despite Cost Pressures From Geopolitical Issues By Optimizing Product And Geographical Mix.

Glenmark Pharma: Expects Steady Growth of 12% to 15% in India with New Products Aumolertinib and Trastuzumab Rezatecan. Company Aims for Around 115 Net Working Capital Days and Zero Gross Debt.

 04 Aug 2026 08:52 AM

Glenmark Pharma: Expects Steady Growth of 12% to 15% in India with New Products Aumolertinib and Trastuzumab Rezatecan. Company Aims for Around 115 Net Working Capital Days and Zero Gross Debt.

GLENMARK PHARMA: Q1 CONS PBT 6.43B RUPEES VS 4.2B (YOY)

 31 Jul 2026 06:50 PM

GLENMARK PHARMA: Q1 CONS PBT 6.43B RUPEES VS 4.2B (YOY)

GLENMARK PHARMA: Q1 CONS NET PROFIT 4.83B RUPEES VS 469M (YOY)

 31 Jul 2026 06:51 PM

GLENMARK PHARMA: Q1 CONS NET PROFIT 4.83B RUPEES VS 469M (YOY)

GLENMARK PHARMA: Q1 REVENUE 40.2B RUPEES VS 32.6B (YOY)

 31 Jul 2026 06:51 PM

GLENMARK PHARMA: Q1 REVENUE 40.2B RUPEES VS 32.6B (YOY)

GLENMARK PHARMA: Q1 EBITDA 7.84B RUPEES VS 5.8B (YOY) || Q1 EBITDA MARGIN 19.51% VS 17.78% (YOY)

 31 Jul 2026 06:51 PM

GLENMARK PHARMA: Q1 EBITDA 7.84B RUPEES VS 5.8B (YOY) || Q1 EBITDA MARGIN 19.51% VS 17.78% (YOY)

Glenmark Pharma: Glenmark Pharmaceuticals Inc. USA Introduces Generic Sugammadex Injection In A $1.6 Billion Annual Market Opportunity

 29 Jul 2026 07:54 AM

Glenmark Pharma: Glenmark Pharmaceuticals Inc. USA Introduces Generic Sugammadex Injection In A $1.6 Billion Annual Market Opportunity

Glenmark Pharma: Expects 70% Of Revenue From Innovative Drugs In 5-6 Years, Highlighting Shift To Innovation-Based Business Model. - ET

 22 Jul 2026 09:04 AM

Glenmark Pharma: Expects 70% Of Revenue From Innovative Drugs In 5-6 Years, Highlighting Shift To Innovation-Based Business Model. - ET

Glenmark Pharmaceuticals: Will Hold Its Q1 Earnings Call On August 3 At 8:30 AM.

 21 Jul 2026 05:33 PM

Glenmark Pharmaceuticals: Will Hold Its Q1 Earnings Call On August 3 At 8:30 AM.

Glenmark Pharma: Co. Gets U.S. FDA Approval to Allow Ryaltris Nasal Spray for Kids Aged 6 to Under 12 Years

 21 Jul 2026 08:53 AM

Glenmark Pharma: Co. Gets U.S. FDA Approval to Allow Ryaltris Nasal Spray for Kids Aged 6 to Under 12 Years

Glenmark Pharma: Glenmark Pharmaceuticals Inc., USA Introduces Olanzapine Injection With Annual U.S. Sales Around $25.4 Million

 06 Jul 2026 09:01 AM

Glenmark Pharma: Glenmark Pharmaceuticals Inc., USA Introduces Olanzapine Injection With Annual U.S. Sales Around $25.4 Million

Glenmark Pharma: Co's Trastuzumab Rezetecan Trial for Platinum-Resistant Ovarian Cancer Gets Phase 3 Approval in India, First Among Licensed Markets.

 02 Jul 2026 08:42 AM

Glenmark Pharma: Co's Trastuzumab Rezetecan Trial for Platinum-Resistant Ovarian Cancer Gets Phase 3 Approval in India, First Among Licensed Markets.

Glenmark Pharmaceuticals: Launches Methylene Blue Injection USP In The USA, Available In 50 MG/10 ML Single-Dose Vial; Product Matches Provayblue® Injection; Provayblue® Market Reached About $19 Million In Annual Sales.

 17 Jun 2026 08:51 AM

Glenmark Pharmaceuticals: Launches Methylene Blue Injection USP In The USA, Available In 50 MG/10 ML Single-Dose Vial; Product Matches Provayblue® Injection; Provayblue® Market Reached About $19 Million In Annual Sales.

Glenmark Pharmaceuticals: Launches Winlevi® Cream For Acne Treatment In Major European Markets; First New Chemical Entity Launch In Europe; Enhances Dermatology Product Range With Direct Market Entries.

 11 Jun 2026 10:22 AM

Glenmark Pharmaceuticals: Launches Winlevi® Cream For Acne Treatment In Major European Markets; First New Chemical Entity Launch In Europe; Enhances Dermatology Product Range With Direct Market Entries.